On July 17, Japan’s Cabinet adopted the 2020 Basic Policy on Economic and Fiscal Management and Reform (honebuto). Its initial text suggested the government’s position to carry out its first off-year drug price revision next April as well as its…
HOME > ACADEMIA
ACADEMIA
- SGLT-2 Inhibitors “Suited to Patients with Tendency to Obesity”: Prof. Kadowaki of Univ. of Tokyo
February 4, 2014
- Japan Hypertension Society Won’t Co-Sponsor or Support Drug Maker-Linked Seminars for Now
January 29, 2014
- JCS’s 2013 Guidelines for Treatment of AF Recommend Dabigatran and Apixaban in Moderate-Risk Patients
January 29, 2014
- SMART Study Should Be Removed from CKD Guidelines: Society Panel Chair
January 22, 2014
- SMART Study Retracted from US Journal, Chief Investigator to Resign as Hospital Director
January 22, 2014
- AJMC Announces Guidelines for COI Management at Research and Medical Institutions
December 25, 2013
- Chiba University Finds No Proof of Manipulation in Diovan Study
December 18, 2013
- Nagoya University Denies Diovan Clinical Data Manipulated
December 16, 2013
- Diovan Probe Updates to Come from Nagoya Univ. on Dec. 13, Chiba Univ. on Dec. 17
December 12, 2013
- New Hepatitis C Guidelines Set Triple Therapy Including Simeprevir as 1st Choice
December 11, 2013
- All Clinical Studies Should Follow GCP Requirements: Ex-AZ Chairman Kato
November 26, 2013
- Edoxaban Demonstrates Non-Inferiority to Warfarin in Stroke Prevention in AF Patients: Daiichi Sankyo
November 22, 2013
- AJMC Approves Draft of COI Management Guidelines
November 20, 2013
- JAMS COI Panel to Nudge JPMA to Create Funding Database
November 19, 2013
- JAMS’ Draft of Revised Guidelines Ups Ante for COI Disclosures in Clinical Trials
November 19, 2013
- Subordinate of Former Employee of Novartis Pharma Participated in SMART Study; Protocol Violations Also Found
November 5, 2013
- Mismatch Found for 10% of ACR Data Between Papers, Patient Records: SMART Study
November 1, 2013
- JSH2014 GL for Management of Hypertension to Emphasize Transparency, Remove References to Discredited Papers
October 29, 2013
- Beta Blockers “Inferior to Other Drugs,” Will Not Be Recommended as 1st–Line Treatments in New Hypertension GL
October 29, 2013
- Skills for Clinical Studies Required to Become Authorized Hypertension Specialist: JSH
October 28, 2013
ページ
Since last year, Japan has seen a number of stock-outs and shortages of generic drugs attributable to API supply disruptions…
Nearly a year after the introduction of the Ministry of Health, Labor and Welfare’s (MHLW) drug promotion guidelines in April…
Advancements in modified oligonucleotide technologies has been the key driver behind a spate of approvals in the oligonucleotide therapeutics space…
Japan’s key reimbursement policy panel on December 20 approved an outline of its FY2020 drug pricing reform next April, with…
The Ministry of Health, Labor and Welfare (MHLW) on November 27 added to the NHI price list Japan’s first biosimilars of Avastin (bevacizumab), Nesp (darbepoetin alfa), and Forteo (teriparatide). The NHI prices of first biosimilars are set at 70% of…
A total of 51 new drugs joined the NHI price list in 2019, which are expected to generate combined peak sales of 373 billion yen, according to Jiho’s tally of data submitted to a key reimbursement policy panel. The relatively…
Some seven years in the making, Japan’s Ministry of Health, Labor and Welfare (MHLW) finally rolled out a cost-effectiveness assessment…
Japan will go ahead with the introduction of a cost-effectiveness assessment (CEA) scheme for drugs and medical devices in April…
In a change striking to the very core of the traditional Japanese salaryman, “We are seeing the coronavirus ushering in a new way of working… and I think it’s about time,” says Ivan Tselichtchev, Professor of Economics at the Niigata…